The uroplakins (UPs) are a family of proteins which associate with each other and form plaques on the apical surface of the urothelium. These plaques contribute to a permeability barrier, preventing the influx of urine from the urinary tract lumen. Urinary tract malformations associated with human and mouse UP mutations, the human fetal expression patterns of UPs and experiments in Xenopus oocytes are collectively revealing new functions for the UPs, forcing us to view these proteins in a new light. Rather than simply being products of the urothelial differentiation program, they may be a group of proteins central to the process of urinary tract differentiation itself. The extreme 'kidney-centric' perspective of the lower urinary tract (i.e. the renal pelvis, ureter, bladder, and urethra) is that it simply represents a 'drain' through which urine flows. This conduit, however, assumes a much greater clinical importance in the context of human congenital malformations because both kidney and lower urinary tract anomalies often coexist: as examples, renal agenesis is often accompanied by absent ureters; hypoplastic (too few nephrons) and dysplastic (immature and metaplastic tissues) kidneys are often attached to atretic, refluxing or duplicated ureters; and, in boys, malformed kidneys commonly occur with urethral valves.
The extreme 'kidney-centric' perspective of the lower urinary tract (i.e. the renal pelvis, ureter, bladder, and urethra) is that it simply represents a 'drain' through which urine flows. This conduit, however, assumes a much greater clinical importance in the context of human congenital malformations because both kidney and lower urinary tract anomalies often coexist: as examples, renal agenesis is often accompanied by absent ureters; hypoplastic (too few nephrons) and dysplastic (immature and metaplastic tissues) kidneys are often attached to atretic, refluxing or duplicated ureters; and, in boys, malformed kidneys commonly occur with urethral valves. 1 In these scenarios, the practices of Nephrology and Urology naturally must be integrated to consider the whole urinary tract as a single entity.
Matching the clinical imperatives of caring for individuals in whom urinary tract development has gone wrong, there is a rich history in which investigators have considered the causes of such human aberrations, beginning with anatomical observations, [2] [3] [4] [5] [6] and then moving on to experimental in vivo [7] [8] [9] [10] and ex vivo [11] [12] [13] [14] manipulations of the developing urinary tract.
Some of the key anatomic observations have been: that kidney, ureter, and bladder development are synchronized; that the mesonephric duct not only gives rise to the ureteric bud, which differentiates into the ureter, renal pelvis, and collecting ducts, but also incorporates with the urogenital sinus, the nascent bladder; that an abnormal trajectory of the ureteric bud correlates with failure of the intermediate mesoderm to form nephrons; and that experimental impairment of fetal urine flow leads to dysmorphogenesis of both the kidneys and bladder. In recent decades, these anatomical observations have been complemented by biological studies, which have again highlighted the harmony of upper and lower urinary tract morphogenesis. As examples: basic processes such as programmed cell death occur in normal upper and lower urinary tract differentiation; 10, 15, 16 and certain molecular signalling systems, such as those mediated by bone morphogenetic proteins and angiotensin II are shared by upper and lower urinary tracts. 17 It is in the above contexts that we here review the uroplakin (UP) family of proteins in relation to normal and abnormal urinary tract development, emphasizing lessons for human congenital disease. The story, which incorporates cell, molecular and developmental biology, along with molecular genetics, should leave one in little doubt that the lower urinary tract is, indeed, rather more complex than tubing through which urine flows.
THE ASYMMETRIC UNIT MEMBRANE AND THE UROPLAKINS
The urothelium is a pseudo-stratified epithelium lining the urinary tract from renal pelvis to the bladder outlet. 18 A peculiar feature is that the luminal leaflet of the apical membrane is twice as thick as the cytoplasmic leaflet, 19 explaining why it is called the 'asymmetric unit membrane'. The asymmetric unit membrane is covered by a crystalline 2D array of protein particles arranged into hexagonal arrays with a distance of 16 nm between the centers of each, forming the 'urothelial plaques' . 20, 21 These plaques are interspersed by regions of membrane that are not asymmetric, called 'hinge regions'. By generating antibodies against crude fractions of bovine asymmetric unit membrane, screening for those which specifically labelled superficial urothelial cells (the criterion originally used to assess specificity for UPs) and affinity-purifying the detergent-soluble fraction using these antibodies, five major products were isolated and their complementary DNAs were characterized. [22] [23] [24] [25] [26] These were referred to as the 'uroplakins', that is, constituents of urothelial plaques. UP-rich plaques are found in the most superficial (i.e. facing the urinary tract lumen) urothelial cells; these are called umbrella cells because of their flat and broad shape. UP1a and UP1b (originally considered a single protein species, 'UPI', as both are approximately 27 kDa) 28 are tetraspanins, having four transmembrane domains that split the protein into one large and one small extracellular domain. UPII (15 kDa), UPIIIa (47 kDa), and UPIIIb (35 kDa) are type I, single-pass transmembrane proteins. The transmembrane topology of the UPs 21,24-26 accounts for the 'asymmetry' of the asymmetric unit membrane because, whereas all UPs have large extracellular domains, only UPIIIa and UPIIIb have significant cytoplasmic domains of 52 and 49 amino acids, respectively. Six UP1a/UPII/UP1b/UPIIIa heterotetramers make up each 16 nm particle, 21 although, in a subset, UPIIIb is substituted for UPIIIa. 23 The identification of the UPs, and the generation of antibodies that specifically recognize them, facilitated exploration of the biophysical relationships within this group of proteins. UPs form specific UP1a/UPII and UP1b/UPIII(a/b) heterodimers, 29 a prerequisite for their normal escape from the endoplasmic reticulum and subsequent transport to the cell surface. 23, 30 Indeed, in UPII or UPIIIa null-mutant mice, there exists disrupted intracellular transport of only the heterodimeric partner of the particular protein encoded by each mutant gene, whereas all other UPs are localized normally at the cell surface; plaque formation is also disrupted. 31, 32 The UPs are glycosylated proteins, and their luminal sugar moieties are modified as they pass along the secretory pathway; the pro-sequence of UPII is cleaved in the Golgi apparatus by furins. 28 UP1b is the only UP that can exit the endoplasmic reticulum of its own accord, 30 although in UPIIIa null-mutant mice it is mistargeted to the basolateral membrane and its sugars are incompletely processed. 31 By facilitating escape from the endoplasmic reticulum, and thus avoiding proteasomal degradation, UP1a and UP1b effectively stabilize their partners, a general property of tetraspanins. 28 Urothelial cells possess 'molecular machinery' that regulates UP processing and transport, and this includes Rab27b, a protein characteristic of differentiated urothelial cells and which colocalizes with UPIIIa directly below the apical membrane. 33 UPs appear to be delivered to the apical urothelial membrane in association with discoidal vesicles, with enhanced delivery to (and removal from) the apical membrane occurring in the urinary bladder as it stretches and fills: in this context, it has been envisaged that UP delivery allows formation of further plaques to cover an increased surface area of urothelium. 34 
UROPLAKINS AS URINARY TRACT BARRIERS
Because descriptive studies had emphasized that UPs were differentiation products of the urothelium, 18 their possible roles, especially as 'barrier molecules', were therefore initially considered in the context of the mature, postnatal urinary tract. Indeed, the 'anti-permeability' hypothesis was supported by Hu et al. 31, 35 who reported that the genetic ablation of UPIIIa in mice not only diminished UP localization in urothelial apical membranes and reduced plaque size but also resulted in increased water and urea permeabilities across this membrane; at the same time, tight junction barrier functions were unaltered.
As described earlier, UPs contribute to the urothelial glycocalyx, so they might, a priori, be considered to constitute a physical barrier, which repels, and prevents the invasion of, bacteria within the urinary lumen. It is therefore notable that pathogenic, type 1 fimbriated Escherichia coli associate with urothelial plasma membrane caveolae and lipid rafts, and that UP1a, a lipid raft component, is a type 1 fimbrial receptor. 36 Furthermore, bacteria can 'hide' in superficial urothelial cells, encased and perhaps even protected by UPs. 37 As these insights were broadening our perception of the roles for UPs in health and disease, the results of two key animal studies, 31, 32 summarized here, were also consistent with roles for these proteins during urinary tract morphogenesis.
UROPLAKINS IN MOUSE URINARY TRACT DEVELOPMENT
Hu et al. 31 generated UPIIIa homozygous null-mutant mice and reported hydronephrosis in young animals: this was accompanied by abnormally wide orifices at the junction of ureters and bladders, hence explaining the presence of vesicoureteric reflux (VUR). A similar urinary tract phenotype was generated by genetic ablation of UPII in mice, 32 a maneuver which led to a complete absence of urinary plaques and umbrella cells. In the same study, it was observed that VUR did not explain all the instances of hydronephrosis and, in some mutant UPII mice, there existed urinary flow impairment associated with urothelial outgrowths in the distal ureter which appeared to occlude the ureteric lumen; in fact, similar outgrowths were also reported in UPIIIa null mice. 32 Furthermore, certain litters of UPII mutants died from renal excretory failure.
UROPLAKINS IN HUMAN URINARY TRACT DEVELOPMENT
These mouse studies led to the consideration of whether UP genes (i.e. either mutations or polymorphisms) might be implicated in human renal tract malformations. Direct sequencing of UP genes failed to reveal mutations in 76 individuals with primary (i.e. not associated with bladder outflow obstruction), non-syndromic (i.e. not part of a congenital multiorgan syndrome) VUR, although the minor allele of a polymorphism in UPIIIa, Pro154Ala, was found to have a significantly elevated frequency in a group of 243 affected individuals when compared to a 'normal control' population. 38 To explore the possible functional significance of this polymorphism, we performed preliminary experiments, expressing variant proteins in COS-1 cells (Figure 1 ). After co-transfection of wild-type UPIIIa with UP1b, UPIIIa was immunodetected on the surface of cells, as expected; after complementary DNA encoding UPIIIa Pro154Ala was cotransfected with UP1b, UPIIIa protein did not appear at the cell membrane, but was retained within cells, giving some credence to putative functional effects of this polymorphism. In another population with primary VUR, however, analyses by transmission-disequilibrium (a more 'genetically robust' methodology than simple association studies) of variants in the promoter and coding regions of UPIIIa (called UPK3 in that study) showed no significant linkage to VUR. 39 In an attempt to find mutations with a major role in renal tract developmental disorders, we turned the focus to individuals with severe renal tract malformations. Three UPIIIa heterozygous mutations were found in four patients with bilateral renal aplasia/dysplasia, without an overt obstruction to urine flow, and all four had severe chronic renal failure. 40 Interestingly, all four mutations appeared to have arisen de novo, being absent in parental leukocyte DNA, firstly confirming the contention that these genetic changes were indeed pathogenic, and secondly providing an explanation for the sporadic nature of disease in these families. Before the advent of advances in dialysis and transplantation, these children would most likely not have survived to pass on their genes, thus emphasizing the potential importance of these findings for genetic counseling in relation to future generations. A follow-up study of a group of children with non-obstructive renal hypoplasia/dysplasia identified a fifth de novo mutation in an individual with unilateral multicystic dysplastic kidney, 41 a condition associated with ureteric atresia. 1, 3 These studies clearly implicate UPIIIa in human congenital disease, and are the first mutations found to cause non-syndromic urinary tract malformations.
DO UROPLAKINS TRANSDUCE SIGNALS IN UROTHELIAL CELLS?
UPII and UPIIIa have been immunolocalized in the normal human fetus from 7 weeks gestation in the urogenital sinus and renal pelvis, 40, 42 and this is the likely onset of UP expression in human urothelium. 43 Together with the human genetic data, described above, these observations raise the possibility that the UPs have a direct role to play in development rather than simply being required for structural integrity.
Recent studies of Xenopus egg fertilization have implicated one of the UPs in signal transduction. 44, 45 Frog UPIIIa (xUPIII) is expressed in the normal egg, ovary, urinary tract, and kidney. On the surface of unfertilized eggs, xUPIII and xUP1b associate with membrane rafts and, upon fertilization, xUPIII is tyrosine phosphorylated on residue 249 in its carboxy-terminal cytoplasmic domain, and this phosphorylation depends on c-Src. Strikingly, biochemical activation and subsequent egg cleavage can be blocked by anti-xUPIII antibodies, consistent with the idea that xUPIII is a sperm receptor. It was subsequently found that cathepsin B, a protease, could biochemically activate frog eggs, inducing phosphorylation of c-Src and xUPIII. Furthermore, cathepsin B partially digests xUPIII, and a synthetic xUPIII peptide, containing a potential proteolytic site, inhibits not only cathepsin B-mediated proteolysis and tyrosine phosphorylation of xUPIII but also sperm-induced egg activation. Therefore, as depicted in Figure 2 , an initial sperm/xUPIII interaction and limited xUPIII proteolysis by sperm protease might be the initiating event in Xenopus oocyte activation. What then are the implications of the frog story for the genetics of human urinary tract malformations? Remarkably, locations of altered amino acids coded by human UPIIIa missense mutations correspond to key parts of xUPIII involved in egg activation, supporting the possibility that mammalian UPIIIa has similar roles in urothelia.
First, UPIIIa has a peptide in the extracellular domain and including part of the transmembrane region which is highly evolutionarily conserved (IDTWPGRRSGGMIV). 41 The GRR residues are the motif cleaved by frog sperm protease 45 and the missense mutation reported by Schonfelder et al. 41 in a child with multicystic dysplastic kidney would code for a Gly202Asp substitution in the corresponding region of the human mutant UPIIIa protein. Working on the hypothesis that human UPIIIa might also transduce signals, perhaps triggered by a putative urinary tract ligand/enzyme, the hypothetical mutant Gly202Asp UPIIIa protein would fail to be proteolytically cleaved.
Second, the recurrent, de novo missense mutation at a cytosine-phosphate-guanosine dinucleotide reported by Jenkins et al. 40 in two children with renal adysplasia is predicted to generate a mutant protein with a Pro273Leu change in the cytoplasmic domain of human UPIIIa. This residue is close to Tyr266, the human residue equivalent to the xUPIII tyrosine, which becomes phosphorylated as a prerequisite for egg activation. Residues 273-277 are actually absent from xUPIII, suggesting that human Pro273 is not directly involved in phosphorylation. Rather, the Pro273Leu mutation may alter the conformation of the cytoplasmic domain of UPIIIa by ablating a 'proline-kink', thus altering the availability of Tyr266 for phosphorylation.
Another provocative insight into the role of UPs is provided by a mouse model of autoimmunity, in which postnatal hydronephrosis was associated with the presence of UPIIIa antibodies which were deposited on urothelia which appeared more-multilayered than normal. 46 The hydronephrosis and urothelial multilayering in this model recall congenital phenotypes in UPII and UPIIIa null-mutant mice. 31, 32 One interpretation of the autoimmune model would be that that the hydronephrosis phenotype is directly related to 'inactivation' of UPIIIa function, and this might be considered the mammalian urinary tract equivalent of antibody-mediated blockade of frog egg activation described by Sakakibara et al. 44 On the other hand, the autoimmune hydronephrosis in mice is accompanied by marked periureteric inflammation, and this, rather than a defect in putative UP signalling, might distort the ureter and contribute to obstruction.
UNANSWERED QUESTIONS AND FUTURE PERSPECTIVES How frequent are UP mutations in individuals with urinary tract malformations?
Jenkins et al. 40 identified UPIIIa mutations in almost onequarter of patients with renal adysplasia who were part of a pediatric renal failure program in London, UK; 40 only one mutation in 170 children with unilateral or bilateral renal hypodysplasia (drawn from Western and Eastern European and Turkish clinics) was found by Schonfelder et al. 41 Therefore, the frequency of UPIIIa mutations appear rather variable depending on the population studied (and perhaps the techniques used to seek mutations), and we suggest that chances of finding a genetic change in UPIIIa may be enhanced by complete sequencing of the gene in children with urinary tract malformations associated with severe renal failure (i.e. Stage V Chronic Renal Disease). Recently, a mutation in UPII was found in another patient with VUR and chronic renal failure from the same London patient group; this was a frameshifted allele (L60fs68X); the genetic change was also found in the index case's mother who had 44, 45 the binding of sperm to full-length xUPIII induces its cleavage by cathepsin B in the so-called conserved region (red box containing the '-GRR-' motif). Cleaved xUPIIIa then serves to phosphorylate the remaining full-length xUPIIIa protein, in the cytoplasmic domain (yellow circled 'P'), in a process that also requires activation of c-Src (also by phosphorylation). Phosphorylated xUPIIIa is required for Xenopus oocyte fertilization, showing that this active form of the protein serves to transduce extracellular cues into cells. Amino-acid changes which would result from reported de novo missense UPIIIa mutations in children with urinary tract malformations 40, 41 are indicated in green. These mutations occur in regions of UPIIIa important for signal transduction in frog eggs, suggesting that UPIIIa might have similar roles in human urothelia. 'Question marks' (in blue) raise questions regarding pathway components in urothelial cells, which might be equivalent to frog egg activation pathways. Note the glycosylation sites (gray circles) on the long, extracellular part of UPIIIa, and the short, cytoplasmic part of UPIIIa, which becomes phorphorylated in oocytes. Key: L, lumenal aspect of the membrane; C, cytoplasmic aspect.
normal renal ultrasonography, but it was absent in 150 healthy Caucasian control individuals. 42 It is possible that this heterozygous change is incompletely penetrant, as is homozygous null mutation of UPII in mice. 32 In future, it will be interesting to analyze the UP gene family in larger unbiased DNA collections from individuals with urinary tract malformations (e.g. The United Kingdom Vesicoureteric Reflux DNA Collection http://www.vur.org.uk) in relation to variations in UP genes. This may reveal genotype-phenotype correlations, offering further insight into the roles of the UPs in development.
What are the functional consequences of UPIIIa mutations?
Despite the human genetic findings outlined above, no study has investigated the precise effects of missense UPIIIa mutations on UPIIIa function. Such studies might serve to illuminate the mode of action of the different alleles, potentially distinguishing dominant-negative effects from a loss-of-function. In this respect, at least two strategies can be envisaged. The first would be to study the biological effects, such as barrier function, state of cell differentiation, and UPIIIa phosphorylation status following the experimental expression of UP variants in more realistic cell types, especially human urothelia in culture. 47 The second would be to generate transgenic mice in which UP alleles are replaced by variants coding for missense changes; specifically, would such animals have clinically relevant urinary tract malformations?
How do UP mutations perturb lower urinary tract development?
With regard to mouse null-mutant studies, it remains unclear precisely how a lack of either UPII or UPIIIa might lead to this range of congenital lower urinary tract anomalies. One theory would rely on the physical properties of UP proteins; specifically, one could postulate that excessive 'leakiness' of the nascent urothelium would allow fetal urine to access surrounding tissues, and damage them. A non-exclusive, alternative explanation would be that UPs act as signalling molecules in the mammalian urinary tract (Figure 2) , analogous to the Xenopus oocyte paradigm. Although there is no evidence that urine is needed for the expression of UPs themselves, 48 postnatal urine does contain cathepsin B 49 and perhaps similar proteases might be present in fetal urine where they might partially cleave UPIIIa. In future, one should seek partially cleaved UPIIIa in developing urinary tracts and also establish whether UPIIIa is tyrosine phosphorylated at any stage of development. We postulate that UPIIIa phosphorylations might somehow alter gene expression, and that this would have an effect on the morphogenesis of adjacent smooth muscle. Certainly, it is well-established that molecules, such as sonic hedgehog, are released by the urothelium and that epithelial-mesenchymal cross-talk enhances smooth muscle growth and differentiation. 50, 51 Further studies on the specialized cell biology of embryonic ureter growth 14 should be encouraged.
How can we explain the association of kidney malformations with UP mutations?
Reporter assays have identified elements of the UP promoters that drive their expression specifically in urothelial cells. [52] [53] [54] Indeed, UPs are not immunodetected within epithelia of the developing human kidney itself, 40, 42 raising the possibility that UP mutations perturb kidney development secondary to structural and/or functional defects of the pelvis and/or ureter. For example, anatomical fetal ureteric obstruction probably occurs in embryonic renal tracts from UPII homozygous null-mutant mice, 32 and this could be a paradigm for a similar situation when an 'atretic' ureter is found attached to a multicystic dysplastic kidney, and this was the renal phenotype observed in the patient carrying the mutation reported by Schonfelder et al. 41 An alternative theory could be that UP mutations lead to 'functional obstruction' of urine flow, a phenomenon documented in experimental animals with anatomically patent urinary tracts which are otherwise functionally defective, often with dysmorphogenesis of ureteric muscle. 51, [55] [56] [57] [58] According to this idea, fetal ureteric myogenic contractions 13, 55 are critical in driving urine from the developing kidney towards the bladder, an especially important phenomenon because the changing orientation of fetuses mean that they can not 'rely on' hydrostatic pressure to move urine down the ureter. In order to investigate this hypothesis, it would be worth investigating the contractility of fetal ureters from UP mutant mice, for example by using explanted embryonic ureters.
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